Skin Research Institute | Clinical Research Site

Research site

(Unclaimed)

Location

4425 Ponce de Leon Boulevard, Suite 200, Coral Gables, Florida, United States of America

Site insights

Top conditions

Top treatments

MT10109L

OnabotulinumtoxinA

AGN-151586

PF-04965842

LIPO-202

AVP-786

Sofpironium Bromide

BOTOX

Izokibep

AXS-07

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 33 total trials

A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

The cumulative effect of aging and environmental exposures (ie, ultraviolet, infrared, and visible light radiation and pollution) leads to wrinkles,...

Active, not recruiting

Neck Lines

Device: VOLITE XC

Locations recently updated

A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower fac...

Enrolling

Masseter Muscle Prominence

Drug: Placebo

Drug: BOTOX

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide \[d6-DM\]/quinidine sulf...

Enrolling

Agitation in Patients With Dementia of the Alzheimer's Type

Drug: AVP-786

Drug: Placebo

Hidradenitis Suppurativa Study of Izokibep

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Placebo

Drug: Izokibep

Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response...

Enrolling

Migraine

Drug: AXS-07 (meloxicam-rizatriptan)

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg